Member Info for D-Geeman

'achievement taking... company share price from 5p to 0.005p (sic) in roughly 2 years '

Some might think it is an achievement. Is that the sound of someone hoovering up cheap shares? Stranger things have happened (as strange anyway).

If I wanted them to stay in 'the most expensive rooms in SF' it'd be because I have shares in Hilton (or whoever).

Not quite the same but:

Business Leaders Known for Flying Economy (or Used To)

Bill Gates: The Microsoft co-founder famously flew economy for years, even after becoming a billionaire, finding first class wasn't significantly better for the much higher cost, though he later embraced private jets for efficiency.

Jim Koch (Boston Beer Co.): The self-made billionaire insists on flying coach and even has his executives fly coach with him, valuing an egalitarian approach.

Ed Bastian (Delta CEO): The high-earning CEO has mentioned choosing economy to be near passengers, catch up on emails, and connect with people, per The Sun.

Steve (Travel Mogul): One travel expert mentioned flying economy for years, finding it "never occurred to me that I'm suffering,".

I hope you invited wisely Yorkshire ;-)

'they are in the most expensive hotel rooms in San Francisco, looking investors in the eye'

I rather hope that's not true NFTs.

Whatever happens here will be in the interets of TB.

So I just bought back a little after selling a few months ago.

Some unusually large buys today. Xeros has been leaky before now though not with new management as far as I recall.

I missed this. Around a week old story:

AccuStem Sciences Announces StemPrintER Pilot Study with National Surgical Adjuvant Breast and Bowel Project (NSABP)

AccuStem Sciences, Inc.

January 8, 2026 4 min read

In this article:

ACUT

-17.26%

AccuStem Sciences, Inc.

AccuStem Sciences, Inc.

Initial study will enable further collaboration on the predictive capabilities of StemPrintER

PHOENIX, Jan. 08, 2026 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer, today announced the execution of a pilot study agreement with NSABP to evaluate StemPrintER in a subset of patients from the B-32 cohort. This evaluation will enable the two groups to then confirm the predictive capabilities of StemPrintER across the full study cohort.

The StemPrintER test interrogates 20 genes to stratify patients with early stage breast cancer according to their recurrence risk. The test was designed to measures the “stemness” of tumors, or how much they behave like stem cells, which may indicate the likelihood of cancer progression and response to standard treatment modalities. Studies have shown that StemPrintER is highly prognostic, with “High Stemness” patients up to 4 times as likely to experience a distant recurrence as “Low Stemness” patients.

“We have a strong foundation of evidence demonstrating the prognostic utility of StemPrintER,” said Wendy Blosser, Chief Executive Officer of AccuStem. “Preliminary in silico work has shown that StemPrintER likely has predictive utility in the surgical setting, so we are partnering with the NSABP - the leader in breast cancer research - to validate those findings. We believe that positive study results could have far-reaching implications for surgical planning in breast cancer.”

The NSABP B-32 trial, which enrolled more than 5,000 patients from 1999 through 2004, was a prospective, randomized study that compared sentinel lymph node resection (SLNR) alone to full axillary lymph node dissection (ALND) for women with early stage breast cancer. The trial found that SLNR alone was equivalent in overall survival and regional control to ALND but resulted in fewer side effects such as nerve damage and lymphedema. Importantly, while patient outcomes on a population level are similar between both study groups, it is reasonable to expect there are a subset of patients who would derive a clinically meaningful benefit from ALND versus SLNR. Thus, this pilot and the larger study represent an ideal opportunity to evaluate sample viability and StemPrintER’s ability to support more informed surgical planning for patients with early stage breast cancer.

“Working with NSABP to identify an unanswered clinical question with potential for a meaningful impact on patient outcomes and treatment planning led us to the B-32 cohort,” said Ms. Blosser. “The NSABP has been on the fore

BTW, CJ (Fall and Rise) thought he could speak German and had been told that 'futhrt' translated to 'further' in En.

Karl Benz's 1886 Patent-Motorwagen, got roughly 24 miles per gallon (mpg),

cars generally achieving poor fuel economy (around 6-12 mpg)

compared to later models like the Model T (13-21 mpg),

"Mr Benz didnt worry about how far his first car went cos it went futhrt than all the rest!" spoken by CJ in Series 2, Fall and Rise of RP. The audience got a bit confused apparently but didn't bother to check the veracity of CJ's claims.

What is stranger?

That Cinders can't read a poster's history (and so makes a fool of themselves) or the builders next door to me are listending to very pleasant classical music?

Also, when I was seaching HC's history yesterrday I ended up making myself 5 minutes late for school collection. Then, as rushing to leave the phone rang and was another neighbour asking for bike pump as his cleaner had a flat tyre. I was quickly able to loan a bike pump.

So BECAUSE of HC's post my neighbour's cleaner was able to cycle home. Amazing.

I'm glad your around break-even Chris. Maybe my day will come too..

'It’s fine anyway, it’s just a bit of fun D, they are big boys that can handle themselves. No need to rush to their defence like some BFF'

If I were ALWAYS rushing to defend people who are misreprented here I'd be a lot more busy posting. Nevertheless you did make a point of drawing attention to someone in a totally misrepresentitive way and others might be here for the first time and actually believe you as you often seem quite a reasonable sort.

Are you still in Stagecoach? Your old post popped up when I was searching 'SGC' and 'Harchris', before you named the company you referenced.

Morning Wyn,

I only just noticed your comments. I've already 'covered' a portion of the cost of the guitar here :-)

Before your comments I sold all my scancell (only a few £100s) at a profit and could now nearly buy them back again despite the fees. The RSI has fallen back a little but still >70. Good place to see if RSI will be kind to me and no problem if it isn't. I know it doesn't always work, after hemo.

I have often made money on Future PLC despite it being in downtrend for quite a while. It's weird. It's always been lucky for me. Opposite effect with Xeros but still keeping fingers crossed.

'Talk' soon no doubt!

Good morning Harc,

Why are you so partial with what you post ;-) It does you no credit.

'19 Dec 2025 11:13

A couple of observations: The odds were in fact of good news to help the SP, so why idi it fall? It fell after the results and fwiw worth I sold 30000 shares on the bell because it was only then apparent it was less than stella news. '

So Wyn actually sold a decent amount of AVCT at around at above 70p (and possibly nearer 80p but not wanting to be partial myself and sonce I don't know let's stick with 70p) while you and I were reading the RNS and thinking "well, that's pretty good news".

And if he held on to some, just in case, wouldn't that also have been pretty understandable?

As for Thorn, who knows where he put the money other than T. But it's well know than what he sold this week in the 50's he'd bought in the 30's.

Are you in profit or are you deep under-water too, like me? When you are well into profit I will take your posts more seriously, that's why I ask...

Half-life; As a layman I'd have thought even if there is a problem there'd be a workaround with dosing. It's not like it's a beauty treatment that has to be particulary convenient as well as effective.

Re: 'posting before going to the pub '

CJ in episode 5 of Fall and Rise of Reginald Perrin;

"School bully days; best years of my life! – Till I realised you don't have to stop when you leave school!!"

Nice DOUBLE cross-ramp here HarC ;-)

'I highlighted the phase 2 SGC trial of another'

I imagine we'd all agree NFTs could teach the Duracell rabbit a thing or two..

Oh I see...

'I suppose there’s no chance of a buyout now as there wasn’t a buyout last month.'

BF looks at the (long anticipated) data, and, and, does nothing, waits for other BF to do something, take the initiative. I confess, I didn't understand that's how BF operates and manages to have £B's in the bank.

Let's see if AVCT get taken over in January 2026 and I will acknowledge your wisdom HC :-)

Finished what I was doing; school run time. Gotta make the best of the time the kids are out

'8 inch response'

WTF?